- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00572572
Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors
Phase III, Double-Blind, Placebo-Controlled, Crossover Study Evaluating Aprepitant in Combination With a 5HT3 & Dexamethasone in Patients With Germ Cell Tumors Undergoing 5 Day Cisplatin-Based Chemotherapy Regimen
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OUTLINE: This is a multi-center trial.
Subjects will be stratified prior to randomization based on previous administration of chemotherapy.
Subjects will randomize to aprepitant or placebo with their first study cycle of chemotherapy and then cross over to opposite treatment with the second study cycle.
Cisplatin-based regimen for germ cell tumors containing 20mg/m2/day IV days 1 through 5, first day of chemotherapy administration is day 1. Permitted treatment regimens:
Regimen 1 (BEP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Etoposide (100 mg/m2/day) IV on days 1 to 5 Bleomycin 30 U/IV on days 1, 8, 15
Regimen 2 (EP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Etoposide (100 mg/m2/day) IV on days 1 to 5
Regimen 3 (VIP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Ifosfamide (1200 mg/m2/day) IV on days 1 to 5 (with mesna uroprophylaxis at 100% ifosfamide dosing) Etoposide (75 mg/m2/day) IV on days 1 to 5
Regimen 4 (VeIP) Cisplatin (20mg/m2/day) IV on days 1 to 5 Ifosfamide (1200 mg/m2/day) IV on days 1 to 5 (with mesna uroprophylaxis at 100% ifosfamide dosing) Vinblastine (0.11 mg/kg/day) IV on days 1 and 2
Regimen 5 (EC) Cisplatin (20mg/m2/day) IV on days 1 to 5 Epirubicin (90 mg/m2/day) IV on day 1
Patients are treated on study for two cycles. At the completion of protocol therapy patients will receive additional chemotherapy at the discretion of the treating investigator.
If a patient requires discontinuation of one medication or more on a regimen, the patient must be discontinued from the study.
Performance Status:
- Not specified
Hematopoietic:
- Not specified
Hepatic:
- Bilirubin < 3 x upper limit of normal
- Aspartate aminotransferase (AST, SGOT) < 3 x upper limit of normal
- Alanine aminotransferase (ALT, SGPT) < 3 x upper limit of normal
- Alk Phos < 3 x upper limit of normal
Renal:
- Serum Creatinine <2 mg/dL
Pulmonary:
- Not specified
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Simon Cancer Center
-
Muncie, Indiana, United States, 47303
- Medical Consultants, P.C.
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- Siteman Cancer Center
-
-
Oregon
-
Portland, Oregon, United States, 97213
- Providence Portland Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
-
Wisconsin
-
Milwaukee, Wisconsin, United States, 53226
- Froedtert/Medical College of Wisconsin
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic, serologic or clinical evidence of germ cell tumor.
- Patients scheduled to receive a 5 day fractionated cisplatin-based combination chemotherapy on permitted regimens
- Prior chemotherapy is allowed. Patients will be stratified based on previous treatment.
- Male patients 15 years of age or older at time of registration.
- Patient will provide written informed consent and authorization to release personal health information.
Exclusion Criteria:
- No known history of anticipatory nausea or vomiting.
- No use of another antiemetic agent within 72 hours prior to beginning chemotherapy.
- No known central nervous system (CNS) metastasis.
- No known hypersensitivity to any component of study regimen.
- No concurrent participation in a clinical trial which involves another investigational agent.
- No use of warfarin while on study.
- No use of agents expected to induce the metabolism of aprepitant which include: Rifampin, Rifabutin, Phenytoin, Carbamazepine, and barbiturates.
- No use of agents which may impair metabolism of aprepitant which include: Cisapride, macrolide antibiotics (Erythromycin, Clarithromycin, Azithromycin), azole antifungal agents (Ketoconazole, Itraconazole, Voriconazole, Fluconazole), Amifostine, Nelfinavir and Ritonavir.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A: Aprepitant, Then Placebo
Participants first received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 1, then received matched placebo PO daily on days 3 through 7 during study cycle 2
|
Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
|
Experimental: Arm B: Placebo, Then Aprepitant
Participants first received matched placebo PO daily on days 3 through 7 during study cycle 1, then received Aprepitant 125mg PO day 3 then 80mg on days 4 and 7 during study cycle 2
|
Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete Response.
Time Frame: Participants were evaluated from start of treatment through day 8 of cycle 2.
|
Participants were followed for chemotherapy induced nausea and vomiting (CINV) through day 8 of cycle 2. Complete response is defined as no emetic episodes and no use of rescue medication.
|
Participants were evaluated from start of treatment through day 8 of cycle 2.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of Patients With no Emesis During the Acute CINV Time Period (Cycle Days 1-5)
Time Frame: Participants were evaluated from cycle days 1-5.
|
Proportion of patients with no emesis regardless of use of rescue medication during cycle days 1-5.
|
Participants were evaluated from cycle days 1-5.
|
Proportion of Patients With no Emesis During the Delayed CINV Time Period (Cycle Days 6-8)
Time Frame: Participants were evaluated from cycle days 6-8.
|
Proportion of patients with no emesis regardless of use of rescue medication during cycle days 6-8.
|
Participants were evaluated from cycle days 6-8.
|
Visual Analouge (VAS) 100mm Scale Score
Time Frame: Days 1-8
|
The Visual Analouge (VAS) 100mm Scale Score for Chemotherapy Induced Nausea and Vomiting (CINV).
Participants were asked to mark a linear scale 100mm in length representing their level of nausea with 0mm indicating no nausea and 100mm indicating severe nausea.
The mean VAS scores for days 1-8 combined, by treatment (Aprepitant vs. Placebo) were reported.
|
Days 1-8
|
MD Anderson Symptom Inventory Score
Time Frame: Days 1-8
|
The MD Anderson Symptom Inventory (MDASI) is a brief measure of the severity and impact of cancer-related symptoms.
Thirteen core items measure the severity of symptoms and six additional items measure the impact of symptoms.
All items are rated on a scale from 0 (not present or did not interfere) to 10 (maximal severity or interference).
The mean value of the total nineteen items ranges from 0 to 10.
|
Days 1-8
|
Preferred Treatment Cycle
Time Frame: 2 months
|
Participants were asked which treatment cycles was preferable - aprepitant or placebo cycle.
|
2 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Lawrence Einhorn, M.D., Hoosier Oncology Group, Inc.
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms, Germ Cell and Embryonal
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Neurokinin-1 Receptor Antagonists
- Aprepitant
Other Study ID Numbers
- QL05-37
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Germ Cell Tumors
-
Astellas Pharma Global Development, Inc.CompletedTumors | Incurable Platinum Refractory Germ Cell TumorsUnited States
-
Memorial Sloan Kettering Cancer CenterMayo Clinic; University of Chicago; University of Pittsburgh; University of Southern... and other collaboratorsActive, not recruiting
-
University Hospital MuensterHannover Medical School; Deutsche Kinderkrebsstiftung; Gesellschaft fur Padiatrische...UnknownIntracranial Germ Cell TumorsGermany
-
Indiana University School of MedicineAstraZenecaTerminatedRefractory Germ Cell Tumors Expressing EGRFUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedBrain and Central Nervous System Tumors | Extragonadal Germ Cell Tumor | Pediatric Germ Cell TumorUnited States
-
Hospital Beatriz ÂngeloBristol-Myers Squibb; Universidade Nova de Lisboa; Instituto de Patologia e Imunologia...Withdrawn
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Ovarian Cancer | Brain and Central Nervous System Tumors | Teratoma | Extragonadal Germ Cell TumorUnited States
-
Centre Francois BaclesseCompletedMetastasis | Non-seminomatous Germ Cell TumorsFrance
-
Heinrich-Heine University, DuesseldorfUnknownStage II A/B Seminomatous Germ Cell TumorsGermany
-
Taizhou Hanzhong biomedical co. LTDNot yet recruitingMelanoma Neuroendocrine Tumors Neuroectodermal Tumors Neoplasms Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms NeoplasmsChina
Clinical Trials on Aprepitant
-
Merck Sharp & Dohme LLCCompletedChemotherapy-Induced Nausea and Vomiting
-
Merck Sharp & Dohme LLCCompletedChemotherapy Induced Nausea and Vomiting
-
The Affiliated Hospital of Qingdao UniversityNot yet recruiting
-
The Hospital for Sick ChildrenCompletedChemotherapy-induced Nausea and VomitingCanada
-
University of VirginiaNational Institute on Drug Abuse (NIDA)CompletedCannabis Dependence | Nicotine Dependence | Marijuana Dependence | Cannabis Abuse | Nicotine WithdrawalUnited States
-
University Hospital, RouenCompleted
-
Sharon WalshNational Institute on Drug Abuse (NIDA); Merck Sharp & Dohme LLCCompleted
-
Duke UniversityMerck Sharp & Dohme LLCCompleted
-
University Hospital Inselspital, BerneRecruitingPostoperative Nausea and Vomiting | Bariatric SurgerySwitzerland